Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow
Portfolio Pulse from
Exelixis reported a 20% increase in net product revenues for Q4'24, reaching $515.2M. The company's 2025 revenue guidance remains flat at $2.15B-$2.25B, not accounting for potential cabozantinib approval for neuroendocrine tumors. The STELLAR-303 trial for zanzalintinib in metastatic colorectal cancer is expected to yield results in H2'25.
February 12, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exelixis reported strong Q4'24 revenue growth, but 2025 guidance remains flat. Potential cabozantinib approval and upcoming zanzalintinib trial results could impact future performance.
The 20% increase in Q4'24 revenues is a positive indicator of growth. However, the flat 2025 guidance suggests potential challenges or conservative forecasting. The potential approval of cabozantinib for neuroendocrine tumors and the results of the STELLAR-303 trial for zanzalintinib could significantly impact future revenues and stock performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100